{"id":390551,"date":"2020-12-01T08:08:17","date_gmt":"2020-12-01T13:08:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=390551"},"modified":"2020-12-01T08:08:17","modified_gmt":"2020-12-01T13:08:17","slug":"outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/","title":{"rendered":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MONMOUTH JUNCTION, N.J., Dec.  01, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4g2FERUAQ0D1MFpvSWfS1MVEHt2dvcADwso-V23Xiajp4S_3mINKd4WGHrRVZlWwsUEVoMbHyyHkMdum2cS7UKkM3FC2V43kHDhG-ATqXzg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics\u2019 common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed.<\/p>\n<p>\n        <strong>About Outlook Therapeutics, Inc.<\/strong>\u00a0<\/p>\n<p align=\"justify\">Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sMblkOCTL-2Fwtgx0KMUc43r_yB0oQS_gWDMRfQLeguygA7XxNS1MgjPzvSmEXBSr-R7Sz3-LQFFdNZRjfFLddKJzoZoHnEecORPgOgYMCKr197Bjs9OCd9GbK7zZlc5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.outlooktherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p>\n        <strong>Media Inquiries:\u00a0<br \/><\/strong>Harriet Ullman <br \/>Assistant Vice President <br \/>LaVoieHealthScience <br \/>T: 617-669-3082\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hM0ndWV_SmdaxoHm3xgupKIzaCzQOqt93IDc8Je2uB26Nddy1Ur67qICiBpR73lGy4z-XkIXVFqqV8P8EaxhHqW60jxA4km88sy7cgts-X8fyVkflpfvKgQNgFjqt94m\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">hullman@lavoiehealthscience.com<\/a><\/p>\n<p>\n        <strong>Investor Inquiries:\u00a0<br \/><\/strong>Jenene Thomas <br \/>Chief Executive Officer <br \/>JTC Team, LLC <br \/>T: 833.475.8247\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wYSzGe5IqmZfTfqVUOM0XgDQR62bDawCzaJ7waNBGcZMBKo0-soCIGtoPSaCwRhXGPnbT9efchjBX5FWMZkniw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">OTLK@jtcir.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2201165c-e5a6-457a-bc82-36e025e30a81\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics\u2019 common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed. About Outlook Therapeutics, Inc.\u00a0 Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-390551","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics\u2019 common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed. About Outlook Therapeutics, Inc.\u00a0 Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If &hellip; Continue reading &quot;Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-01T13:08:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement\",\"datePublished\":\"2020-12-01T13:08:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/\"},\"wordCount\":235,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/\",\"name\":\"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\",\"datePublished\":\"2020-12-01T13:08:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","og_description":"MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics\u2019 common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed. About Outlook Therapeutics, Inc.\u00a0 Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If &hellip; Continue reading \"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-01T13:08:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement","datePublished":"2020-12-01T13:08:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/"},"wordCount":235,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/","name":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=","datePublished":"2020-12-01T13:08:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDE1OCMzODQ5MTcyIzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=390551"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=390551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=390551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=390551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}